Preliminary web-based measures development for GHB: Expectancies, functions, and withdrawal
Date of Original Version
Background: Much of what is understood regarding gamma hydroxybutyrate (GHB) treatment is based on hospital case studies for overdose and withdrawal, and there are currently no measures developed specifically for GHB or its analogs (e.g., gamma butyrolactone and 1,4-butanediol) to assess drug effect expectancies, reasons for starting use, withdrawal effects, and knowledge and opinions about use. Objectives: This pilot study (N = 61) was conducted to begin measures development to assess experiences, functions of use, and opinions regarding use as indicated by respondents taking a Web-based survey. Methods: Minimum average partial correlation and parallel analysis procedures are employed to create scales. Results: Scales were developed to assess expectancies, reasons for use, withdrawal, and knowledge/opinions of use with median α = .79 and that account for 8.69-24.17% of the variance. Conclusion: Scales have relatively good psychometric properties and replication is needed. Scientific Significance: GHB-specific measures may greatly assist in furthering our understanding of protective and risk factors for use, and withdrawal phenomena. Copyright © Informa Healthcare USA, Inc.
American Journal of Drug and Alcohol Abuse
Stein, L. A., Rebecca Lebeau, Mary Clair, Rosemarie Martin, Monte Bryant, and Susan Storti. "Preliminary web-based measures development for GHB: Expectancies, functions, and withdrawal." American Journal of Drug and Alcohol Abuse 38, 2 (2012): 121-129. doi:10.3109/00952990.2011.643970.